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INTRODUCTION

In the present study, we have conducted a genome-wide DNA
methylation analysis to describe the DNA methylation changes
in PCa. We have investigated potential mechanisms by which
differentially methylated genes may be involved in the development of PCa, by examining pathway enrichment and protein
interactions. In addition, we have addressed mechanisms that
regulate the establishment of differentially methylated regions
(DMRs) in PCa by investigating the transcription factor (TF)binding patterns nearby the identified segments. Also, we report
the copy number variations (CNVs) recurrently happening in
PCa and evaluate their associations with the methylation levels of
the overlapping DMRs. Finally, using the most differentiating
CpGs, we have generated a classification model to distinguish
the tumors from the adjacent benign tissues, and have validated
this algorithm using a large independent cohort of benign and
tumor prostate samples.

Prostate cancer (PCa) is the most common malignancy in men,
representing the third greatest cause of mortality in the general
population after lung and colorectal cancer (1). Current screening
protocols for PCa rely on digital rectal examination along with the
evaluation of serum levels of prostate-specific antigen. If a tumor
is suspected, trans-rectal, ultrasound-guided, prostate needle
biopsies are conducted, followed by a histopathology examination. Major limitations of this approach include a relatively high
false negative rate and the requirement for annual follow-ups and
repeat sampling, an invasive approach with significant burden on
patient health care and lifestyle (2). As such, a significant effort
has been made to identify more accurate diagnostic and screening biomarkers for PCa, though to date this effort has been met
with limited success in clinical application (3).
Among the markers that have gained interest in disease
screening is DNA methylation, an epigenetic mechanism that
includes modification of the fifth base of cytosine at cytosinephosphate-guanine (CpG) dinucleotide in the DNA by addition
or removal of a methyl group. DNA methylation plays an integral
role in the regulation of gene expression and genomic stability,
disruption of which can lead to neoplastic transformation, carcinogenesis, and cancer progression (4). The relative stability of
the DNA molecule together with the genome-wide distribution
of DNA methylation marks has made it an attractive target for
disease biomarker discovery (5). DNA methylation has proven to
possess a great potential in the prediction of many human traits
and conditions, including age, postpartum depression, childhood
stress exposure, tumor class, response to therapy, and cancer
progression/metastasis (5).
Epigenetic changes have been previously demonstrated in
multiple cancers including PCa (6), with epigenomic signatures
of PCa being proposed to be used as both diagnostic and prognostic markers (3, 7). PCa-associated DNA methylation changes
have also been found in the urine and serum of patients, raising
hopes for non-invasive methods of PCa screening (3). These
methylation changes have been found in various genes involved
in hormonal response, cell-cycle regulation, cell invasion, and
DNA damage repair (6). In particular, hypermethylation in the
promoters of tumor suppressor genes APC, RARβ, and GSTP1,
has been proposed to be used as a diagnostic marker for PCa
(8). However, these assays have not generated optimal performances, partly because they target selected candidate genes
instead of markers discovered in a genome-wide search. The
number of studies attempting to produce a diagnostic methylation algorithm for PCa using a genome-wide approach is limited. Furthermore, few studies have conducted a comprehensive
genome-wide DNA methylation analysis to reveal the role of
DNA methylation in PCa (3).
Frontiers in Oncology | www.frontiersin.org

MATERIALS AND METHODS
Specimen Collection

Archival formalin-fixed paraffin-embedded tissues were collected from the Department of Pathology at McMaster University,
ON, Canada. The slides were reviewed by a pathologist to identify
representative tumor tissue blocks. Enrichment of tumor cells
was performed by tissue macro-dissection of predetermined
areas, as outlined by Haemotoxylin and Eosin staining. Sevenmicron thick sections in isolated areas of interest with at least
50% tumor cellularity were dissected to be used as tumor samples.
Normal prostate samples were obtained from the adjacent tissues
demonstrating no tumor involvement.

Methylation Assay and Quality
Assessment

Genomic DNA extraction was conducted using the Illumina
FFPE DNA recovery kit. Following bisulfite conversion, DNA
methylation analysis of the samples was performed using the
Illumina Infinium methylation 450 k bead chip array (San Diego,
CA, USA), according to the manufacturer’s protocol. Both
tumor and normal samples were assayed in one experiment to
avoid batch effect. The resulting methylated and unmethylated
signal intensity data were imported into R 3.4.2 for analysis.
Normalization was performed using Illumina normalization
method with background correction using the minfi package (9).
Probes with detection p-value > 0.01, and those known to contain
single nucleotide polymorphisms at the CpG interrogation or
single nucleotide extension were removed. All of the samples
were examined for genome-wide methylation density, and those
deviating from a bimodal distribution were excluded. Factor
analysis using multiple dimensional scaling did not reveal any
2
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Identification of DMRs in PCa

unexplained variation or outliers among the samples. The raw
and processed genome-wide methylation microarray data has
been deposited to gene expression omnibus (GEO) (accession
ID: GSE112047).

To identify genomic regions harboring methylation changes
(DMRs), a bump-hunting approach was used by the bumphunter
package (22). The analysis considered regions with >20% change
in the overall methylation between tumor and normal samples
with gaps no more than 500 bp among neighboring CpGs. As
suggested by the package, 1,000 bootstrapping procedures were
performed to compute family-wise error rate (FWER). We
selected regions containing a minimum of three consecutive
probes and FWER < 0.01. The identified regions were mapped
to CpG islands and coding genes. Gviz package was used for
visualization of the DMRs.

Identification of a PCa-Related
Methylation Profile

DNA methylation analysis was performed using a modification of our previously published protocol (10–15). Methylation
level for each probe was measured as a beta value, calculated
from the ratio of the methylated signals vs. the total sum of
unmethylated and methylated signals, ranging between 0
(no methylation) and 1 (full methylation). This value was used
for biological interpretation and visualization. For statistical
analysis, beta values were logit transformed to M-values
using the following equation: log2 (beta/1 − beta). A linear
regression modeling using the limma package (16) was used
to identify the differentially methylated probes by testing the
association of every CpG site with the level of tumor involvement (0–90%). The generated p-values were moderated using
the eBayes function in the limma package and were corrected
for multiple testing using Bonferroni method. Probes with a
corrected p-value < 0.01 and a methylation difference > 20%
were considered significant. The effect size cut-off (20%)
was determined following the examination of the volcano
plot of the analysis, as conducted in our previous study (17).
The identified probes were examined using an unsupervised
hierarchical clustering to ensure their ability in separating the
tumors from normal samples.

Identification of Copy Number Changes
Using DNA Methylation Array

To estimate the copy number alterations in the prostate tumor
from the Infinium methylation array, the raw methylated and
unmethylated intensities from every sample were summed, and
quantile normalized using the preprocessCore package (23). The
normalized matrix values were divided by the median values of
every probe across the normal samples. The divided ratios were
then log10 transformed, smoothed, and segmented using the
DNAcopy Bioconductor package (24) to identify genomic regions
in every sample showing a copy number change. A p-value of
<0.01 obtained from 10,000 permutations was used to define a
change point during segmentation. The segmented regions with
a minimum of five probes and an average log ratio > 0.2 or <−0.3
(corresponding to at least one copy amplification/deletion) were
selected. Using the GenomicRanges package (25), the segments
with a similar pattern of copy number change in both normal
and tumor samples were excluded. Segments on chromosome
six, overlapping HLA genes, were not considered due to normal
variations in their copy numbers. From the remaining segments,
those occurring in more than one tumor sample were reported.

Gene Enrichment Analysis and
Identification of Differential Methylation
Interaction Hotspots

To identify the gene ontology (GO) terms overrepresented in
the genes harboring differentially methylated probes, a gene-set
enrichment analysis was performed using the missMethyl package (18), taking into account the number of CpG sites per gene.
GO terms with a Bonferroni corrected p-value <0.01 were considered significant. Only the biological processes were reported.
The redundant GO terms were reduced, and following a multiple
dimensional scaling, visualized using REViGO tool (19). The
relationships across the significant GO terms were plotted in a
hierarchical order using GORILLA tool (20).
We used EpiMod algorithm (21) to search for the “interactome
hotspots” of differential promoter methylation. In this algorithm,
protein expression changes are inferred according to a model
of inverse association between the promoter methylation and
gene expression. Among the differentially expressed genes in an
interactive network, a hotspot [or epigenetic module (EpiMods)]
is a sub-network with an exceptionally large average edge-weight
density (combined methylation statistics of the neighboring
genes) as compared to the rest of the network (21). To assign
a statistical significance to the identified hotspots, 1,000 Monte
Carlo randomization of the molecular profiles were conducted
as suggested by the algorithm. Interactive network hotspots
composed of at least ten genes and FDR < 0.01 were reported.
Frontiers in Oncology | www.frontiersin.org

TF-Binding Site Enrichment Analysis
in DMRs

We investigated the enrichment of TF-binding motifs in both
the identified DMRs and their immediate surroundings (±5 kb)
using the pipeline recommended by the RTFBSDB package (26).
First, the entire direct and inferred Homo sapiens TF-binding
motifs were downloaded from the Cis-BP database (27). Every
DMR sequence and its ±5 kb surroundings were scanned for
motif enrichment relative to a background genome of 100,000
base pairs. As recommended by the package, the difference in
the GC content of the DMRs and the background genome was
accounted for by re-sampling of the background genome to avoid
a potential bias due to GC content. The motifs with an enrichment ratio ≥1.5 folds and a Bonferroni corrected p-value < 0.01
were selected for assessment.

Construction and Validation of a
DNA Methylation-Based Diagnostic
Model for PCa

The differentially methylated probes were used to build a classification model to differentiate tumor samples from the normal
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Material; Figure 1A). Out of these CpG sites, only 27 (0.4%)
showed a hypomethylation change. The vast majority of these
probes were annotated to a coding gene (n = 4,334, 70.2%). A
significant number showed an association with regulatory features, including 5,011 (81.2%) being located in or nearby a CpG
island, 1,959 (31.7%) being annotated to DNase Hypersensitivity
Sites, and 2,000 (32.3%) located in an enhancer element. Using
an unsupervised hierarchical clustering, these probes were shown
to be able to completely separate the two groups. The degree of
hypermethylation was observed to be correlated with the level of
tumor cellularity (Figure 1B). A correlation analysis between the
mean methylation levels of the entire profile and tumor cellularity
revealed a Pearson correlation coefficient of 0.92 (Figure S1 in
Supplementary Material).

tissues. Only CpG probes located outside the regions with
copy number change were utilized for feature selection. First,
a receiver operating characteristic curve analysis (ROC) was
performed to identify the most differentiating probes. Those
probes with an area under the curve (AUC) of 1.00 were retained.
Next, pairwise correlations among the remaining probes were
measured to identify and exclude the redundant features with
R-squared >0.90. A least absolute shrinkage and selection operator (LASSO) was used to further narrow down the features and
train the model, using the glmnet package (28). Following 1,000
permutations, the shrinkage parameter of lambda with lowest
misclassification error was selected and incorporated into the
final model. The model was set to generate probability scores
ranging 0–1, representing the chance of a given sample being
a tumor. The default binary classifier’s probability threshold of
0.5 was used as classification cut-off. To assess the performance
of the model, publically available methylation data from normal
and tumor prostate tissues, benign prostate hyperplasia (BPH),
and samples of PCa metastasis in other tissues were downloaded
from GEO and blindly supplied to the model. Based on the
scores and classifications produced by the algorithm for these
samples, we measured accuracy, sensitivity, specificity, and AUC
as indices of performance for our classifier. The GEO accession
IDs and their related publications of the methylation data files
used for validation of our algorithm are mentioned here to
give credit to the researchers providing these data. Tumor and
adjacent benign array files were downloaded from GSE76938
(29), GSE52955 (30), GSE47915 (31), GSE55479 (32), GSE83917
(32), and GSE38240 (33). The normal prostate array data from
radical prostatectomy due to bladder cancer, and those with BPH
were obtained from GSE55599 (34). Methylation data of tissues
with metastases from prostate were included in the files from
GSE38240 (33).

Cell Communication Is the Central
Functional Entity of PCa Methylation
Profile

Gene-set enrichment analysis of the CpG sites with differential
methylation identified 466 enriched GO terms (biological
processes) with a multiple testing corrected p-value < 0.01,
considering the number of probes in every gene (Table S2 in
Supplementary Material). The most frequent terms in this list
include various forms of cell–cell communications, growth,
senescence, bone morphogenetic protein signaling, neurogenesis, and differentiation (Figure 2). Protein interaction analysis
of the differentially methylated promoters using the EpiMod
algorithm identified a total of 9 genes as a hotspot for protein–
protein interactions containing a minimum of 10 interacting
partners and an FDR < 0.01 (Tables S3 and S4 in Supplementary
Material; Figure S2 in Supplementary Material). Among these
are genes known to be involved in carcinogenesis, including
C-X-C motif chemokine ligand 5 (CXCL5), estrogen-related
receptor gamma (ESRRG), and sclerostin domain containing 1.
The most active hotspot, however, was found for collagen
type-3 alpha-1, located at the center of an interactive network
of COL5A2, COL5A1, COL11A1, COL11A2, PCOLCE, and
HTRA1, all being members of extracellular matrix regulation
pathways (Table S4 in Supplementary Material; Figure S2 in
Supplementary Material).

Ethics Statement

This study has been approved by the Hamilton Integrated Research
Ethics Board (#14-700-T). All of the samples and records were
de-identified prior to analysis.

RESULTS
Study Cohort

Genomic Regions Differentially Methylated
(DMRs) in PCa

The study cohort included 31 samples of archival prostate gland
tissue with a confirmed diagnosis of prostate adenocarcinoma,
assessed by a licensed pathologist. From 16 of these, adjacent
normal tissues were collected to be used as the control group.
The tumor sections were dissected ensuring a minimum of 50%
cancer involvement using macrodissection. There was no overall
difference between the age of the subjects in the control group
(55.7 ± 7.3) and the tumor group (55.2 ± 9.9).

Using a bump hunting approach, we found 613 genomic coordinates containing a minimum of three consecutive CpGs, an average regional methylation difference >0.2, and a FWER < 0.01
(Table S5 in Supplementary Material). All of these regions were
hypermethylated, and the vast majority was mapped to coding
genes and CpG Islands. Among the largest and most differentially
methylated segments are hypermethylation in the promoters
of tumor suppressors (APC, 10 probes, 30%; KLK10, 4 probes,
28%), genes involved in regulation of cellular senescence (HIF3A,
8 probes, 31%), cell communication and adhesion [protocadherin (PCDH) gene cluster (n = 88), 3–9 probes, 21–36%], and
genes regulating the growth including PDE4D (6 probes, 23%)
and estrogen receptor-related gamma (ESRRG, 6 probes, 24%).

PCa Generates a Hypermethylation Profile

From a total of 440,532 CpG probes that passed the quality
controls, a total of 6,167 were revealed to have a methylation
difference of >20% between the two groups with a multiple
testing corrected p-value <0.01 (Table S1 in Supplementary
Frontiers in Oncology | www.frontiersin.org
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Figure 1 | Differentially methylated cytosine-phosphate-guanine (CpG) sites in prostate cancer: (A) volcano plot of the comparison between the tumors and benign
samples: X-axis: methylation difference (mean tumor − mean normal); Y-axis: negative logarithmic scale of p-value; vertical dashed lines: methylation difference
cut-off (0.2); horizontal line: p-value cut-off (0.01, Bonferroni-corrected). The significant probes are shown in red; (B) Heatmap of the tumors (columns, blue bar), and
the adjacent benign tissues (columns, red bar) using 6,167 differentially methylated loci (rows): intensity of blue color corresponds to the methylation levels. Numbers
bellow columns: level of tumor cellularity.

DMRs in PCa Are Surrounded by Tumor
Suppressor-Binding Motifs

In addition, a number of chromatin regulators such as histone
deacetylase 9 (HDAC9, 6 probes, 26%) and TET1 (4 probes, 31%),
as well as genes coding for histone subunits (HIST1H-1A, 3G,
4D, and 4F) were found to show increased methylation in their
promoters (3–7 probes, 22–27%).

Analysis of 1,946 Homo-sapiens-specific TF-binding motifs from
the Cis-BP database revealed that the DMR sequences rarely
bind to any of these TFs. Similarly, a TF-binding site enrichment
analysis found an inverse enrichment for any of these motifs
among these DMR sequences (enrichment ratios < 1, data not
shown). We hypothesized that this might be related to the possibility that DMRs are not a direct target for regulatory elements;
rather, they occur as a result of cis-regulation by TFs binding to
the sites around them. Therefore, we expanded the DMRs by
5 kb upstream and downstream and re-analyzed the data. We
found enrichment for 25 motifs specific to 18 TFs (minimum
fold change: 1.5, Bonferroni corrected p-value < 0.01, Figure 4).
Except for few being chromatin regulators (CGBP, MBD2, and
DNMT1), all of these TFs were found to have tumor suppressor
functionality (BRCA1, E2F1&2&5&7, EGR1-4, FLI1, NRF1,
TFDP2, and STAT1), or indirectly mediate the suppression of
tumorigenesis and tumor suppressor activity (SP4 and ZBTB33).

Copy Number Changes (CNVs) in
PCa Correlate With DMR Status

Copy number analysis identified a total of 33 segments in the
tumor samples containing a minimum of five markers and one
copy of loss/gain, observed in more than one tumor (Table S6
in Supplementary Material). Most of these regions were located
nearby coding genes. Out of these, two segments, one in chr2:
29338077–29338258 and the other in chr15: 45421860–45422325,
annotating to CLIP4 and DUOX1, were most recurrently amplified among the tumors (in seven and eight samples, respectively).
Comparison of the CNV and DMR lists revealed that both of
these regions also show an increased level of methylation (Table
S5 in Supplementary Material; Figure 3). The same incidence was
also observed for regions in the promoters of KRT3 and PLEC
(each amplified in three tumors), but not among other CNVs.
For instance, a segment in the promoter of PNCK (amplified in
three tumors) did not reveal any hypermethylation change. These
results suggested that the hypermethylation pattern seen in some
of the DMRs might be associated with their CNV status.

Frontiers in Oncology | www.frontiersin.org

A Four-CpG Classification Model
Enables Accurate Diagnosis of PCa

To design a classification model with the ability of detecting PCa
tumor status from methylation profile, we first performed feature
selection from the significant PCa-related probes and then trained
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Figure 2 | Gene-set enrichment analysis of differentially methylated cytosine-phosphate-guanine sites (CpGs) in prostate cancer: (A) multiple dimensional scaling
of the gene ontology (GO) terms (circles): GO terms with closely related functionalities are clustered in groups. Circles with smaller distance from each other
represent GO terms with similar functionality. The uniqueness of every GO term is shown using a color scale from blue (less unique) to red (more unique).
Representative non-redundant GO terms from every cluster are written next to the related circles. Only 350 of the GO terms were selected by REVIGO for reduction
and visualization (maximum software limit); (B) hierarchical relationship between the significant GO terms: the level of significance (p-value) of every functional
category is illustrated by a color scale from white to blue.

(Figure 5C). Altogether, this analysis revealed a sensitivity of
0.96 (9 false negatives in 234 tumors), specificity of 0.98 (2 false
positives among 74 adjacent benign, 6 BPH, and 10 normal),
an overall accuracy of 0.97, and AUC of 0.98 for the validating
dataset (Figure 5B). Among other files available from GEO were
arrays from bone (n = 3), lymph node (n = 2), and soft tissue
(n = 1) with metastases from PCa, all of which were confidently
predicted to have a methylation profile similar to PCa. In addition, a total of 61 technical replicates of the prostate tumors were
available from datasets GSE83917 and GSE55479. Prediction
scores generated for these files remained consistent with their
original pairs, including the false negatives, suggesting that our
model is not sensitive to technical variation. The prediction
scores for all of the above array files are presented in Figure 5C
and Tables S8 and S9 in Supplementary Material.

a LASSO model with a binary outcome (tumor vs. normal). To
avoid a potential bias from the variations in DNA copy numbers,
we excluded the probes located in CNV regions. Next, we selected
the non-redundant and fully differentiating probes (AUC = 1.00),
which resulted in the retention of 46 CpGs. These probes were
incorporated into a LASSO model, which following penalization,
assigned coefficients equal to 0 to 42 of the probes, dropping them
out of the model. Therefore, the final model was trained using
four CpGs (Figure 5A) on 16 normal samples and 31 tumors
(model details in Table S7 in Supplementary Material). These four
CpGs are located in the first intron of OLFM1, promoter of RFX7,
12th intron of PTPRN2, and the promoter of FLOT1, respectively
(Table S7 in Supplementary Material).
To test the model, we first assessed its performance on the
training data. As expected, all of the samples were assigned a
correct classification of tumor vs. benign (accuracy, sensitivity,
specificity, and AUC of 100%; Figure 5B). Next, to validate
our algorithm, we downloaded DNA methylation array data
of prostate samples publically available from GEO, and blindly
supplied their methylation levels from the four CpGs to our
model for classification. Of a total of 234 tumor and 76 benign
prostate arrays (adjacent tissue to tumor) that we found in GEO,
the algorithm correctly classified 225 as having a tumor profile
and 74 as being benign, respectively. Next, we downloaded six
normal prostate arrays from radical prostatectomy due to bladder cancer and ten arrays from BPH samples and supplied them
to our model, all of which were classified as normal, suggesting
that our algorithm can also differentiate BPH from the tumor

Frontiers in Oncology | www.frontiersin.org

DISCUSSION
In this report, we have described DNA methylation changes in
PCa as compared to the adjacent benign tissue and reported a
hypermethylation profile, which is overrepresented in genes and
interactive networks that regulate cell–cell signaling, cell communications, growth, and differentiation. Our study has revealed
that the DMRs in PCa do not directly overlap regulatory elements; instead, they are surrounded by TF binding motifs specific
to tumor suppressors. And finally, we have demonstrated that by
using as few as four CpGs one can accurately classify prostate
specimens as malignant or benign.
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Insights Into the Involvement of DNA
Methylation in PCa

all stages of the disease, likely due to selection pressure (29, 35).
Previous reports have also found that, in contrast to the
hypermethylated CpGs that will gain further methylation during tumor progression, hypomethylation events are less likely

A hypermethylation profile has been reported by previous DNA
methylation studies of PCa, which appears to be maintained in

Figure 3 | Continued

Frontiers in Oncology | www.frontiersin.org
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Figure 3 | Correlation between copy number variation (CNV) status and DNA methylation in prostate cancer: hypermethylation in the promoter of the CLIP4
gene partially correlates with its CNV status. The figure illustrates a segment in the promoter of CLIP4 gene, located in the short arm of chromosome 2. The
region is marked with high levels of acetylation of the 27th lysine residue of Histone 3, (H3K27Ac), a maker associated with active promoters. The segment is
also recognized as a cytosine-phosphate-guanine (CpG) island (green pane). Panels (A,B) represent 181 base-pairs of this segment, harboring a total of 8 CpG
probes, which were identified to concurrently show both hypermethylation and CNV amplification. (A) The color scale of the vertical bars (each probe)
represents the log ratios of the copy numbers. The color scale above 0.2 is shown with red and indicates a minimum of one copy amplification for the region.
Color scales of white and light blue represent no CNV change (we defined a CNV loss with a log ratio less than −0.3, which is not observed for this region).
Samples are sorted from top to bottom. The top 16 samples represent normal tissues and the lower samples indicate the tumors (vertical pane as an indicator:
blue and pink). Within this segment, the right five probes show CNV amplification in tumors, but not in the adjacent benign tissues. (B) The methylation status
of the same eight probes shows a hypermethylation in tumors (pink) relative to normal adjacent benign tissues (blue). Methylation level of every probe from
every sample is presented with a dot, representing a methylation range between 0 and 1 (bottom to top). Lines represent mean, and shadows around the lines
indicate 95% confidence intervals of the mean in every group. The region with CNV amplification is significantly hypermethylated; however, this
hypermethylation extends beyond the CNV to three probes in the upstream.

Figure 4 | Motifs enriched within ±5 kb of differentially methylated regions: TF, transcription factor; N. Pos.: number of observed motifs; expected: number of
expected motifs; enrichment: fold enrichment; p-value is corrected for multiple testing using Bonferroni method. Motifs are sorted by fold enrichment.

Frontiers in Oncology | www.frontiersin.org
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Figure 5 | Prediction algorithm for classification of prostate samples: (A) four cytosine-phosphate-guanine (CpG) probes selected by LASSO for training the
classification model show significant hypermethylation in the tumors as compared to the normal samples. Y-axis represents the methylation levels. (B) The
classification model yields 100% accuracy [area under the curve (AUC) = 1.00] in the training dataset and 97% accuracy (AUC = 0.98) in the validating dataset of 92
benign samples and 234 tumors (model details in Tables S7 and S8 in Supplementary Material); (C) classification scores generated by the model for 16 normal
samples in the training dataset (Benign T), 31 tumor samples in the training dataset (Tumor T), 76 benign tissue from validating dataset (Benign V), 234 tumors from
validating dataset (Tumor V), 6 normal radical prostatectomy from validating dataset (Normal RP), 10 benign prostate hyperplasia (BPH) from validating dataset,
6 prostate cancer metastasis from bone, lymph node, and soft tissue (Metastasis), as well as 61 tumor technical replicates are shown using violin-jitter plots. Y-axis
represents the tumor probability scores (0–1), stratified by different classes on the X-axis. Violin-jitter plots show the density and distributions of the scores in every
category. The normal samples mostly receive a score between 0.15 and 0.45, while the majority of the tumors are scored >0.65. The default cut-off of 0.5 (dashed
line) is used for classification. Only two of the normal samples out of 92 received a score similar to other tumors, and only 9 misclassifications out of 234 have been
made for tumors. Technical replicates have also generated comparable scores to the samples in the original experiment.

Frontiers in Oncology | www.frontiersin.org
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to be maintained in the more advanced stages of the disease
(33). Consistent with these results, we observed that the level
of hypermethylation in PCa directly correlates with the degree
of tumor cellularity in the primary prostate specimens (Figure
S1 in Supplementary Material). The postulated link between a
hypermethylation profile and cancer is a model of translational
silencing of tumor suppressors by promoter hypermethylation
(6). Indeed, we have observed increased methylation in the promoters of several tumor suppressor genes including APC (Figure
S3 in Supplementary Material), a well-characterized tumor suppressor gene associated with familial adenomatous polyposis, and
KLK10, which has been shown to repress proliferation and induce
apoptosis in PCa cells (36). Among other DMRs in genes involved
in growth and differentiation in our study are PDE4D, encoding
a signal transduction molecule with cyclic-AMP phosphodiesterase activity that is shown in mice to promote proliferation of
PCa (37). As well, we have observed promoter hypermethylation
in ESRRG, which was also found to act as a hotspot for protein–
protein interactions. Downregulation of ESRRG has been found
in certain types of prostate carcinomas, and it has been shown
that its increased expression can repress tumor proliferation
regardless of androgen sensitivity (38).
Besides tumor suppressors with a potential role in cell
growth and proliferation, analyses of gene-set enrichment
and protein–protein interaction hotspots have revealed that
methylation changes in PCa encompass a combination of biological processes extending beyond the regulation of growth
to neurogenesis and cell–cell communication. The best-known
involvement of neurons in cancer is perineural invasions,
where tumor invades the neural tissue. Another form of
neural involvement in cancer, namely neurogenesis, has been
recently reported in prostate tumors as the formation of neural
components, axonogenesis, and increased number of neurons
(39). Neurogenesis has been found to correlate with both perineural invasions and poor clinical outcomes in PCa (39). Our
gene enrichment analysis contains multiple GO terms related
to the development of the nervous system, including brain
development, axonogenesis, and neurogenesis. In parallel,
these analyses provide evidence for the involvement of diverse
forms of cell–cell signaling and communications, ranging from
regulation of the extracellular matrix to chemotaxis and cellular
response to stimuli. Among all of the genes in our results that
are known to take part in these processes, the PCDH genes
are mutually involved in both neurogenesis and cell–cell communications. Our DMRs contain extensive regions that overlap
the promoters of close to 90 PCDH gamma genes and isoforms.
Various members of this cluster have been shown to be present
in cell–cell adhesion, neural stroma and synapses (40), and
homophilic trans-interactions (41). Overexpression of PCDHs
in vitro has been demonstrated to suppress Wnt signaling and to
inhibit colony formations of cancer cells (42). Limited data suggest an involvement of PCDH 8, 11, and PC in PCa; however, no
information is available regarding the PCDH gamma genes in
PCa (43–45). Hypermethylation of various subtypes of PCDH
gamma promoter is reported in Wilms’ tumor, colorectal carcinoma, uterine leiomyosarcoma, esophageal adenocarcinoma,
and Barrett’s esophagus (46).
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Overall, the major biological mechanisms that can be inferred
from the methylation changes in this study represent the driver
events, required for the maintenance, integrity, and survival of the
tumor rather than those that may initiate tumorigenesis resulting
from the loss of tumor suppressor functions. Similarly, the most
recurrent CNV changes in tumors were found as amplifications
in the promoters of DUOX1, a NADPH oxidase involved in
the maintenance of tissue homeostasis (47), as well as CLIP4,
an intracellular linker protein whose knock-down has been
shown to increase cell migration and viability in clear cell renal
cell carcinomas (48). These two segments were also found to be
hypermethylated, potentially by the expansion of the CG repeats
or methylation quantitative trait loci resulting from CNV amplification (4). Therefore, some of the hypermethylation changes
we have observed in PCa might be related to the CNV status of
the regions. However, the more common phenomenon that is
potentially involved in the establishment of the DMRs appears to
be a dysregulation following a change in tumor suppressor activity. The interesting finding that almost the entire enriched motifs
nearby DMRs are specific to tumor suppressors indicates that
DMRs in PCa, which mainly represent cancer driver events, are
potentially generated or maintained secondary to a dysregulation
in tumor suppressors’ function.

Clinical Implications of the 4-CpG
Classification Model

The current method widely in use for the diagnosis of PCa is an
8–12 core needle biopsy, which is well known to encompass a
high false-negative rate (49). A significant number of cancer-free
reports of the prostate biopsies are shown to be at risk of having an
undiagnosed PCa (49). Approximately 25–50% of these men are
diagnosed with PCa in a second biopsy performed within 1 year
(50). On the other hand, a positive needle biopsy is not confidently
replicable. Serefoglu et al. have shown that a repeat PCa diagnosis
can be made only in 67.8% of biopsies from post-operative prostate
glands of men undergone radical prostatectomy due to PCa, using
the same 12-core mapping as performed pre-operatively (51). The
main reason for this discrepancy is the spatiotemporal, molecular,
and morphological heterogeneity of the prostate adenocarcinoma
that leads to a non-uniform presentation of the tumor by the
involved tissue (52). This indicates that a significant portion of
negative biopsies can contain molecular changes associated with
cancer without completely representing histological features of
adenocarcinoma (53, 54), and thus a reliable biological marker
would assign a diagnosis to a considerable number of suspicious
samples undiagnosed following histopathology examination.
Consistent with this, Troyer et al. was among the first to publish a report that DNA methylation markers can detect PCa in
histopathologically cancer-negative prostate tissues of men who
went on to have subsequently positive biopsies (55). Within a
few years of this report, methylation markers in the promoters
of GSTP1, APC, and RASSF1 were introduced as a commercial
tissue-based assay to identify patients in need of repeat biopsies
(56). However, clinical validation studies of this assay have only
revealed a sensitivity of 68% and a specificity of 64% (57, 58),
questioning the reliability of a candidate gene approach in PCa
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screening. We have also observed hypermethylation to a variable
extent in all these three genes (Tables S1 and S5 in Supplementary
Material); however, this is not consistently found across all specimens (Figure S3 in Supplementary Material for APC), thereby
resulting in reduced sensitivity for cancer tissue specification. As
a consequence, efforts to identify DNA methylation biomarkers
shifted toward a genome-wide approach for PCa. Goh et al.
(59), following a genome-wide DNA methylation analysis, have
proposed a 55-CpG classification model, which has yielded 89.8%
sensitivity and 66.7% specificity in the validation step. More
recently, Kirby et al. have reported a 3-CpG model for classification of tumor samples from the adjacent benign tissues, which
reached a sensitivity of 90% and specificity of 82% as measured
in a validation cohort of 49 benign and 213 tumor samples (29).
Here, we have further improved the classification of prostate
samples by designing a 4-CpG classification model, which has
revealed 100% accuracy in separating tumors from benign tissue
in our internal dataset. The validation of this model using heterogeneous cohorts of 326 prostate samples from publically available
resources has revealed 96% sensitivity and 98% specificity with
an overall accuracy of 97% (AUC = 0.98). To our knowledge, this
far supersedes performance of any reported DNA methylationbased algorithm for the diagnosis of PCa. Our model is sensitive
enough to detect PCa metastasis in other tissues, including bone,
soft tissue, and lymph nodes (Figure 5), while it is still specific
enough to discriminate BPH from the tumor. This method can
be used to develop a low-cost high-throughput targeted assay for
diagnosis of PCa or to complement the pathological examination of cancer-negative needle biopsies. It may also be used for
confirmation of metastatic lesions outside of the prostate.

biopsies. In order to make this technology more broadly applicable,
its accuracy should be demonstrated on limited amounts of DNA
obtained from needle biopsy specimens, and address whether the
performance is similar across the biopsy specimens and the entire
prostate gland. Another important aspect to assess is whether
this assay can detect neoplastic transformation in specimens that
appear to be normal in an initial pathological examination, but
are demonstrated to harbor tumor in subsequent assessments of
the same core (i.e., false negatives).
The markers and methodology presented here could be
expanded to research applications with the aim of developing
novel approaches in the non-invasive screening of PCa using
circulating tumor DNA. The study we have described herein
reveals the power of high-throughput genomic technologies,
in combination with machine learning, to increase our understanding of the biology of cancer and, at the same time, to
provide us with novel, precise approaches for cancer screening
and diagnosis.
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Future Directions

The current classification algorithm presented in this study is
designed and validated using tumor samples and normal adjacent
tissues obtained from radical prostatectomy. Before this method
is translated into clinical use, further computational training,
validation, and clinical trials are required. First, the performance
of the model needs to be assessed on samples with diverse ranges
of tumor cellularity. In the present study, we did not assess samples
with tumor involvement less than 50%, and thus, the accuracy
remains unknown with regards to samples with lower levels of
tumor cellularity. In a small subset of the tumor samples in the
validation dataset, we observed scores close to the ones found in
normal tissues, which might be caused by a potentially low level
of tumor cellularity in them. Computationally, we can re-train
the algorithm to enable the prediction of tumor cellularity as a
continuous measure. In addition, the model will have to be tested
and potentially re-trained on DNA obtained from needle core
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